Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | CCKBR | P32239 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7834014 | 0.69 | CCNE2 (0.44) | JAK2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL8773953 | 0.69 | CCNE2 (0.44) | JAK2GABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL68595 | 0.69 | CA12 (0.45) | JAK2NOS2CA12CA9BRPF1 | |
| Hydrochloric Acid SCHEMBL2034214 | 0.67 | CA12 (0.43) | JAK2NOS2CA12CA9BRPF1 | |
| Hydrochloric Acid SCHEMBL10863156 | 0.67 | CA12 (0.43) | JAK2NOS2CA12CA9BRPF1 | |
| SCHEMBL9381489 | 0.67 | GABRA1 (0.39) | JAK2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL9378707 | 0.66 | CYP11B1 (0.44) | JAK2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL9201794 | 0.66 | MAOA (0.48) | JAK2NOS2CA12CA9BRPF1 | |
| Hydrochloric Acid SCHEMBL7397522 | 0.66 | CA12 (0.42) | JAK2NOS2CA12CA9BRPF1 | |
| SCHEMBL17257956 | 0.66 | CA12 (0.42) | JAK2NOS2CA12CA9BRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438064-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | Novartis AG (CH) | 2012-04-11 | — | — | EP | claimed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | claimed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | claimed |
| US-20230330027-A1 | PHARMACEUTICAL PREPARATION | MERCK PATENT GMBH (DE) | 2023-10-19 | — | — | US | disclosed |
| EP-3277681-A1 | IMIDAZOLONYL QUINOLINES AND USE THEREOF AS ATM KINASE INHIBITORS | Merck Patent GmbH (DE) | 2018-02-07 | — | — | EP | disclosed |
| WO-2017194632-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
| WO-2016182810-A1 | COMBINATION THERAPY FOR CANCER | ELI LILLY AND COMPANY (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016155884-A1 | IMIDAZOLONYL QUINOLINES AND USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-10-06 | — | — | WO | disclosed |
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2438064-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| EP-2129379-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS | Novartis AG (CH) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009118324-A1 | 5IMIDAZOQUINOLINES AND PYRIMIDINE DERIVATIVES AS POTENT MODULATORS OF VEGF-DRIVEN ANGIOGENIC PROCESSES | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2008103636-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | CAPRARO HANS-GEORG | 2007-09-13 | — | — | US | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | PI4KA, PDPK1, PI4KB | JAK2 218/4885NOS2 1969/4885GABRA1 3121/4885 |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | ABL1, PRKCA, PRKCQ | JAK2 89/4885NOS2 2479/4885GABRA1 2358/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | JAK2 264/4885NOS2 1195/4885GABRA1 3903/4885 |
| US-20230330027-A1 | PHARMACEUTICAL PREPARATION | CYP3A7, CYP2C8, CYP3A5 | JAK2 604/4885NOS2 3343/4885GABRA1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.